7 Best Beauty Stocks to Buy Right Now

4. Hims & Hers Health, Inc. (NYSE:HIMS)

Number of Hedge Fund Holders: 35     

Analysts’ Upside Potential as of January 9:  26.09% 

Hims & Hers Health, Inc. (NYSE:HIMS) is among the Best Beauty Stocks.

TheFly reported on January 8, 2026, that BofA reduced the price target for Hims & Hers Health, Inc. (NYSE:HIMS) to $29 from $32. It retained an Underperform rating on the stock. The firm claims that the consensus expectations for sales and EBITDA margins in 2026 are excessively high. It notes that 2026 will be Hims & Hers’ “big investment year” and that projections for an increase in EBITDA margin seem excessively optimistic. BofA expects negative earnings revisions in the upcoming months and risks of downside to 2026 revenue and EBITDA margins.

Citi reported on January 5, 2026, that the corporation was once more left off of Novo Nordisk’s partner list for the Wegovy weight loss pill’s U.S. launch. It also includes CVS Health, Costco, LifeMD, and GoodRx. This exclusion is possibly due to differences between Novo and the company’s compounded semaglutide strategy. In 2026, Citi forecasts that the Wegovy launch will put pressure on Hims & Hers Health, Inc. (NYSE:HIMS) GLP-1 business. The firm remains to have a $30 price target and a Sell rating. In the premarket, the stock was trading at $33.85, up $0.44.

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the top telehealth firms in the United States.